CIHR – POR Awards – Transition to Leadership Stream – Phase 2

Well-being, Health and Biomedical Discovery


Academic Unit: Inquire with your unit

Memorial Deadline: Contact RGCS for deadline

External Deadline: Tuesday 5th, October 2021


Timelines: To minimize gaps in funding when transitioning from Phase 1 to Phase 2, applicants must carefully review the program deadlines below to understand which deadline is most applicable to their situation considering their Phase 1 Award end date and their desired Phase 2 Award start date.

Awardees must consider the following information:

  • The start dates below are currently based on the terms and timelines of active Phase 1 Awards. Note that all funding start dates must be on the first day of the month.
  • Any decision by Phase 1 Awardees to submit their application later than their applicable deadline (e.g., to submit at the next available deadline) will likely result in a gap in funding between their Phase 1 and Phase 2 Awards.
  • Phase 2 Award funding cannot begin until after the end date of the Phase 1 Award.

For a Phase 2 Award start date:

  • Between April 1, 2022 to August 1, 2022, the Phase 2 application deadline is October 5, 2021 (anticipated Notice of Decision (NOD) is March 1, 2022);
  • Between September 1, 2022 to December 1, 2022, the Phase 2 application deadline is March 1, 2022 (anticipated NOD is August 1, 2022);
  • Between January 1, 2023 to July 1, 2023, the Phase 2 application deadline is July 5, 2022 (anticipated NOD is December 1, 2022);
  • Between August 1, 2023 to October 1, 2023, the Phase 2 application deadline is January 31, 2023 (anticipated NOD is July 2, 2023);
  • Between November 1, 2023 to August 1, 2024, the Phase 2 application deadline is May 2, 2023 (anticipated NOD is October 1, 2023);
  • On September 1, 2024, the Phase 2 application deadline is March 5, 2024 (anticipated NOD is August 1, 2024).

For example, if the applicant’s Phase 1 Award end date is March 31, 2022 and the applicant is planning to begin the Phase 2 Award on April 1, 2022, the application must be submitted by October 5, 2021.

After reading the full funding opportunity below, applicants should contact CIHR as soon as possible if they have questions regarding the duration of their Phase 1 Award, do not see their Phase 2 start date within the deadline list, wish to confirm which of the Phase 2 deadlines is most appropriate for them, and/or have any other questions.


The Strategy for Patient-Oriented Research (SPOR) is a national coalition of federal, provincial and territorial partners (patients and informal caregivers, health authorities, academic health centres, charities, philanthropic organizations, private sector, etc.) dedicated to the integration of research into care.

Patient-oriented research, which is foundational to evidence-informed health care, refers to a continuum of research that engages patients as partners, focusses on patient-identified priorities and improves patient outcomes. This research, conducted by multidisciplinary teams in partnership with relevant stakeholders, aims to apply the knowledge generated to improve healthcare systems and practices.

The vision for SPOR is that Canada will demonstrably improve health outcomes and enhance the health care experience for patients through the integration of evidence at all levels of the health care system. The CIHR Strategic Plan 2021-2031 sets a vision of best health for all, powered by outstanding research. Through the objectives of this funding opportunity and the application of a patient-oriented research approach, SPOR will contribute to the acceleration of several CIHR Strategic Plan priorities, more specifically Priority B: Strengthen Canadian Health Research Capacity; Priority C: Accelerate the Self-Determination of Indigenous Peoples in Health Research; and Priority E: Integrate Evidence in Health Decisions.

Patient-Oriented Research Awards – Transition to Leadership Stream

The Patient-Oriented Research Awards – Transition to Leadership Stream is one funding component of the SPOR Capacity Development Initiative. The aim of the POR Awards is to support the timely career launch of the next generation of patient-oriented researchers.

The awards are comprised of two phases and the total duration of the award across the two phases is fixed at six years. Phase 1 provides funding for a stipend and research allowance, including professional development training (up to three years); Phase 2 provides a contribution to the salary and research allowance (up to four years).

This funding opportunity is for the Phase 2 portion of the award; it is open only to individuals currently holding a Phase 1 award from the 2019 POR Awards – Transition to Leadership Stream competition (201911TLS) and who are ready to transition into their independent patient-oriented research career.

CIHR has planned for Phase 2 applications based on the start dates and durations of Phase 1 awards (see program deadlines under the Notices section). However, CIHR acknowledges that the COVID-19 pandemic has disproportionally affected trainees and early career researchers and may have an effect on this important transition period. In preparation of Phase 2, Phase 1 Awardees may determine the following:

  • They are not ready to apply for Phase 2 at the anticipated deadline.
    • As such, CIHR will permit a gap of up to 12 months between the end date of Phase 1 and start date of Phase 2, at the request of Awardees. The total number of years of funding remains six years.
  • They need additional time in Phase 1, i.e., the training phase.
    • As such, Phase 1 Awardees with two-year award durations may request up to an additional year in Phase 1, thereby reducing the amount of funding available in Phase 2. The total number of years of funding remains six years.
  • They are able to transition to Phase 2 earlier than anticipated.
    • As such, Phase 1 Awardees with three-year award durations may request to reduce their Phase 1 duration by up to one year. The total number of years of funding remains six years.

Regardless of the applicable situation, Awardees are asked to: 1. contact CIHR to request changes to their Award no later than four months in advance of the end of the Phase 1 Award; and, 2. apply to one of the existing program deadlines for Phase 2 specified in the Notices section.

Patient-Oriented Research Approach Requirements and Alignment with the CIHR Strategic Plan

Applications submitted to this funding opportunity are required to demonstrate the following key aspects of a patient-oriented research approach and building capacity for patient-oriented research:

  • Co-Conducting Impactful Research with Health System StakeholdersRecognizing research outcomes matter to patients and should aim to improve health care, the research must be done in partnership with patients as well as relevant health care professionals, health system administrators, and other stakeholders. This work, in particular, requires developing a robust patient engagement plan that includes appropriate mechanisms and budget to support and enable patient engagement throughout the project, including clear roles and responsibilities, compensation/payment, and training.
  • .
  • Equity, Diversity and InclusionCIHR is committed to promoting the inclusion and advancement of groups underrepresented in science as one of the means to enhance excellence in research, training and knowledge mobilization. CIHR’s position on equity, diversity and inclusion (EDI) is available in the Tri Agency Statement on Equity. Phase 2 proposals must outline measures for how members of groups underrepresented in science will be meaningfully engaged in research, training and knowledge mobilization activities, as appropriate.
  • .
  • Indigenous Health ResearchAll Indigenous Health Research in Phase 2 must be conducted by, grounded in, or engage with Indigenous communities (i.e., First Nations, Inuit, Métis, and/or Urban Indigenous communities), societies and/or individuals and their wisdom, cultures, experiences and/or knowledge systems, as expressed in their dynamic forms, past and present. It must also demonstrate appropriate consideration of TCPS 2: Chapter 9 – Research Involving the First Nations, Inuit and Métis Peoples of Canada and other Indigenous ethical guidelines, as well as meaningful and culturally safe research designs, practices, plans and activities throughout the research project(s).
  • .
  • Career/Professional DevelopmentApplications must demonstrate the necessary environment, mentorship and training components that will support the continued development of patient-oriented research competencies and skills, including those relevant to Indigenous Health Research where applicable. For example, Phase 2 award recipients are encouraged to participate in professional development that aligns with the key knowledge areas/competencies and specific skills, as set out in Phase 1. Opportunities may be offered through the SPOR National Training Entity (SPOR NTE), and, if appropriate, through other organizations.

As in Phase 1, Phase 2 award recipients are required to continue their partnership with the SPOR NTE to develop and maintain their personal career development plans. This partnership includes:

  • Undertaking regular progress reviews with the SPOR NTE;
  • Participating in coaching and mentoring opportunities with the SPOR NTE; and
  • Participating in national meetings or workshops hosted by the SPOR NTE.
  • Additional information can be found here.

Funding Sources

Canadian Institute of Health Research (CIHR)

This opportunity was posted by: RGCS

Last modified: May 4, 2021